Compare Lupin Ltd with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs CIPLA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN CIPLA LUPIN/
CIPLA
 
P/E (TTM) x -73.3 20.2 - View Chart
P/BV x 2.2 2.3 96.5% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 LUPIN   CIPLA
EQUITY SHARE DATA
    LUPIN
Mar-19
CIPLA
Mar-19
LUPIN/
CIPLA
5-Yr Chart
Click to enlarge
High Rs986678 145.4%   
Low Rs720484 148.9%   
Sales per share (Unadj.) Rs369.5198.2 186.4%  
Earnings per share (Unadj.) Rs13.418.5 72.4%  
Cash flow per share (Unadj.) Rs37.435.0 106.9%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs303.7186.3 163.0%  
Shares outstanding (eoy) m452.49805.70 56.2%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.32.9 78.8%   
Avg P/E ratio x63.631.4 203.0%  
P/CF ratio (eoy) x22.816.6 137.5%  
Price / Book Value ratio x2.83.1 90.1%  
Dividend payout %016.2 0.0%   
Avg Mkt Cap Rs m386,064468,031 82.5%   
No. of employees `00017.722.6 78.1%   
Total wages/salary Rs m31,51328,565 110.3%   
Avg. sales/employee Rs Th9,453.87,053.1 134.0%   
Avg. wages/employee Rs Th1,782.01,261.5 141.3%   
Avg. net profit/employee Rs Th343.0659.1 52.0%   
INCOME DATA
Net Sales Rs m167,182159,710 104.7%  
Other income Rs m3,6404,766 76.4%   
Total revenues Rs m170,822164,475 103.9%   
Gross profit Rs m28,82230,973 93.1%  
Depreciation Rs m10,85013,263 81.8%   
Interest Rs m3,0781,684 182.8%   
Profit before tax Rs m18,53420,791 89.1%   
Minority Interest Rs m-89-172 52.0%   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,0175,695 158.3%   
Profit after tax Rs m6,06614,924 40.6%  
Gross profit margin %17.219.4 88.9%  
Effective tax rate %48.727.4 177.6%   
Net profit margin %3.69.3 38.8%  
BALANCE SHEET DATA
Current assets Rs m138,536124,266 111.5%   
Current liabilities Rs m61,29937,715 162.5%   
Net working cap to sales %46.254.2 85.3%  
Current ratio x2.33.3 68.6%  
Inventory Days Days8491 92.4%  
Debtors Days Days11295 118.5%  
Net fixed assets Rs m127,516105,190 121.2%   
Share capital Rs m9051,611 56.2%   
"Free" reserves Rs m136,517148,511 91.9%   
Net worth Rs m137,422150,123 91.5%   
Long term debt Rs m66,41738,301 173.4%   
Total assets Rs m279,494239,633 116.6%  
Interest coverage x7.013.3 52.6%   
Debt to equity ratio x0.50.3 189.4%  
Sales to assets ratio x0.60.7 89.7%   
Return on assets %3.36.9 47.2%  
Return on equity %4.49.9 44.4%  
Return on capital %8.911.8 75.3%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41457,410 103.5%   
Fx outflow Rs m22,28219,041 117.0%   
Net fx Rs m37,13238,368 96.8%   
CASH FLOW
From Operations Rs m16,66016,911 98.5%  
From Investments Rs m-32,825-16,687 196.7%  
From Financial Activity Rs m7,441-3,487 -213.4%  
Net Cashflow Rs m-8,724-3,451 252.8%  

Share Holding

Indian Promoters % 46.6 16.0 291.3%  
Foreign collaborators % 0.2 20.8 1.0%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 31.9 23.7 134.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.1 26.2 38.5%  
Shareholders   98,259 161,166 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Realty and Oil & Gas Stocks Witness Selling(Closing)

India share markets recovered some losses during closing hours today and ended their day marginally lower.

Related Views on News

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Feb 27, 2020 (Close)

TRACK LUPIN

LUPIN - STRIDES PHARMA SCIENCE COMPARISON

COMPARE LUPIN WITH

MARKET STATS